Biotech Business - September 16, 2026
Circio raises NOK 200 million for in vivo CAR-T program
Circio Holding has completed a private placement raising approximately NOK 200 million in gross proceeds, earmarked to accelerate a new in vivo CAR-T cell therapy programme built on the company's circVec circular-RNA platform.
Collaboration - April 7, 2026
Norwegian collaboration in radiopharmacy against cancer
Thor Medical has entered into a multiyear frame agreement with Node Pharma for the supply of radium-224 and lead-212 for preclinical use.
MedTech Business - December 3, 2025
Photocure wins the Norwegian Cancer Society Innovation Prize
Ingrid Stenstadvold Ross, Secretary-General of the Norwegian Cancer Society, presented the innovation award, accompanied by a prize of NOK 300,000, to the bladder cancer company Photocure. “Building on our success and expertise, we aim to create a suite of complementary precision diagnostic solutions to address the evolving needs of patients, physicians, and the broader healthcare […]
Biotech Business - August 27, 2025
Nykode Therapeutics announces updated strategy
The updated strategy includes prioritization of VB10.16 as the lead clinical asset and value driver, given the company’s increasing conviction in its potential to treat HPV16 positive cancers.
Acquisition - August 5, 2025
BerGenBio and Oncoinvent to merge
On June 30 2025, BerGenBio and Oncoinvent announced that they have entered into a merger agreement to combine the two companies through a statutory merger, where BerGenBio will be the acquiring entity.
Agreement - March 28, 2025
OncoZenge in agreement for the commercialization of BupiZenge in Europe
The company has entered into a binding agreement with Molteni Farmaceutici regarding exclusive rights to commercialize BupiZenge in Europe.
